CSPC Pharma (01093) announced that the company's developed Pabocinib tablets (125mg) have obtained the Drug Registration Approval issued by National Medical Products Administration of China and are recognized as drug consistency evaluation of generic drugs.

Pabocinib is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, which blocks cells from entering S phase from G1 phase, thereby reducing cell proliferation of estrogen receptor (ER)-positive breast cancer cell lines. The product is suitable for locally advanced or metastatic breast cancer with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative, and needs to be used in combination with aromatase inhibitors as initial endocrine therapy for postmenopausal women. Compared with Pabocinib capsules, this product does not need to be taken with food and can eliminate the drug interaction with proton pump inhibitors.

The approval of this product will further enrich the group's product line in the field of anti-tumor.